Ferastral, an iron-poly (sorbitol-gluconic acid) complex, in the treatment of severe iron-deficiency anaemia in pregnancy.
Thirteen pregnant women with iron-deficiency anaemia have been treated with Ferastral. In a further seven women, Ferastral was given 24 hours before delivery, when induction of labour was indicated, to investigation of iron concentration in maternal serum, cord blood and amniotic fluid simultaneously. The efficacy of Ferastral was demonstrated by a significant increase in haemoglobin and haematocrit. No serious reactions occurred and no evidence was found of disturbance of liver or renal function. It was shown that Ferastral does not pass the placental barrier and that no direct transport takes place through the uterine wall or amnion. No effects on the newborn were demonstrated.
D000293:Adolescent; D000328:Adult; D000653:Amniotic Fluid / Q000032:analysis; D000747:Anemia, Hypochromic / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005312:Fetal Blood / Q000032:analysis; D005942:Gluconates / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D007273:Injections, Intramuscular; D007501:Iron / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008431:Maternal-Fetal Exchange / Q000187:drug effects; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D013012:Sorbitol / Q000627:therapeutic use
D004338:Drug Combinations; D005942:Gluconates; D013012:Sorbitol; D007501:Iron